Biomarkers and Parkinson's disease

被引：115

作者：

Michell, AW ^{[1
]}

Lewis, SJG ^{[1
]}

Foltynie, T ^{[1
]}

Barker, RA ^{[1
]}

机构：

[1] Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England

来源：

BRAIN | 2004年 / 127卷

基金：

英国医学研究理事会;

关键词：

biomarkers; Parkinson's disease; diagnosis;

D O I：

10.1093/brain/awh198

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.

引用

页码：1693 / 1705

页数：13

共 157 条

[1] Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease [J].

Abe, T ;

Isobe, C ;

Murata, T ;

Sato, C ;

Tohgi, H .

NEUROSCIENCE LETTERS, 2003, 336 (02) :105-108

[2] Huntington's disease progression PET and clinical observations [J].

Andrews, TC ;

Weeks, RA ;

Turjanski, N ;

Gunn, RN ;

Watkins, LHA ;

Sahakian, B ;

Hodges, JR ;

Rosser, AE ;

Wood, NW ;

Brooks, DJ .

BRAIN, 1999, 122 :2353-2363

[3] Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease [J].

Antonini, A ;

Leenders, KL ;

Vontobel, P ;

Maguire, RP ;

Missimer, J ;

Psylla, M ;

Günther, I .

BRAIN, 1997, 120 :2187-2195

[4] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[5] AN INVENTORY FOR MEASURING DEPRESSION [J].

BECK, AT ;

ERBAUGH, J ;

WARD, CH ;

MOCK, J ;

MENDELSOHN, M .

ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&

[6]

Becker G, 2001, MOVEMENT DISORD, V16, P23, DOI 10.1002/1531-8257(200101)16:1<23::AID-MDS1003>3.0.CO

[7]

2-2

[8] INCIDENTAL LEWY-BODY-DISEASE [J].

BENSHLOMO, Y ;

WENNING, G .

LANCET, 1994, 344 (8935) :1503-1503

[9] Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell [J].

Berendse, HW ;

Booij, J ;

Francot, CMJE ;

Bergmans, PLM ;

Hijman, R ;

Stoof, JC ;

Wolters, EC .

ANNALS OF NEUROLOGY, 2001, 50 (01) :34-41

[10] Echogenicity of the substantia nigra -: Association with increased iron content and marker for susceptibility to nigrostriatal injury [J].

Berg, D ;

Roggendorf, W ;

Schröder, U ;

Klein, R ;

Tatschner, T ;

Benz, P ;

Tucha, O ;

Preier, M ;

Lange, KW ;

Reiners, K ;

Gerlach, M ;

Becker, G .

ARCHIVES OF NEUROLOGY, 2002, 59 (06) :999-1005

← 1 2 3 4 5 6 7 8 9 10 →